NO895087L - Fremgangsmaate for fremstilling av terapeutisk aktive cykliske eter-derivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive cykliske eter-derivater.

Info

Publication number
NO895087L
NO895087L NO89895087A NO895087A NO895087L NO 895087 L NO895087 L NO 895087L NO 89895087 A NO89895087 A NO 89895087A NO 895087 A NO895087 A NO 895087A NO 895087 L NO895087 L NO 895087L
Authority
NO
Norway
Prior art keywords
eter
derivatives
procedure
preparation
therapeutic active
Prior art date
Application number
NO89895087A
Other languages
English (en)
Other versions
NO895087D0 (no
Inventor
Annie Hamon
Original Assignee
Ici Pharma
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Pharma, Ici Plc filed Critical Ici Pharma
Publication of NO895087D0 publication Critical patent/NO895087D0/no
Publication of NO895087L publication Critical patent/NO895087L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO89895087A 1988-12-23 1989-12-18 Fremgangsmaate for fremstilling av terapeutisk aktive cykliske eter-derivater. NO895087L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88403311 1988-12-23

Publications (2)

Publication Number Publication Date
NO895087D0 NO895087D0 (no) 1989-12-18
NO895087L true NO895087L (no) 1990-06-25

Family

ID=8200452

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89895087A NO895087L (no) 1988-12-23 1989-12-18 Fremgangsmaate for fremstilling av terapeutisk aktive cykliske eter-derivater.

Country Status (17)

Country Link
US (1) US5098932A (no)
EP (1) EP0375457B1 (no)
JP (1) JPH03135976A (no)
AU (1) AU622965B2 (no)
CA (1) CA2006095A1 (no)
DE (1) DE68913940T2 (no)
DK (1) DK665089A (no)
ES (1) ES2063149T3 (no)
FI (1) FI896015A0 (no)
GB (1) GB8927287D0 (no)
HU (1) HUT52494A (no)
IE (1) IE63211B1 (no)
IL (1) IL92580A (no)
NO (1) NO895087L (no)
NZ (1) NZ231666A (no)
PT (1) PT92701A (no)
ZA (1) ZA899688B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902113A1 (en) * 1989-07-18 1991-06-19 Ici Plc Diaryl ether cyclic ethers
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
CA2058254A1 (en) * 1991-01-15 1992-07-16 John Francis Kingston Benzodioxole derivatives
US5258399A (en) * 1991-01-17 1993-11-02 Imperial Chemical Industries Plc Sulphonamide derivatives
IL100483A0 (en) * 1991-01-17 1992-09-06 Ici Plc Sulphonamide derivatives
EP0505122A1 (en) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, alpha-dialkylbenzyl derivatives
EP0532239B1 (en) * 1991-09-10 1995-12-13 Zeneca Limited Benzenesulphonamide derivatives as 5-lipoxygenase inhibitors
EP0555067A1 (en) * 1992-02-07 1993-08-11 Zeneca Limited Hydroxylamine derivatives as 5-lipoxygenase inhibitors
GB9300894D0 (en) * 1992-02-07 1993-03-10 Zeneca Ltd Oxime derivatives
CA2094465A1 (en) * 1992-04-23 1993-10-24 Pierre Andre Raymond Bruneau Cycloalkane derivatives
CA2095005A1 (en) * 1992-05-12 1993-11-13 Philip Neil Edwards Hydroxylamine derivatives
CA2095006A1 (en) * 1992-05-12 1993-11-13 Philip Neil Edwards Oxime derivatives
US5231197A (en) * 1992-06-01 1993-07-27 General Electric Company Method for producing ethylenically unsaturated graftable orthoesters
DE4228201A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Leukotrien-B¶4¶-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU4444393A (en) * 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
WO1994005638A1 (en) * 1992-09-02 1994-03-17 Abbott Laboratories Trans 1,4-diether cyclohexane inhibitors of 5-lipoxygenase
US5407959A (en) * 1993-11-12 1995-04-18 Abbott Laboratories (Trans-1,4-dialkoxycyclohexyl) substituted arylalkylaryl-arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US5446062A (en) * 1993-11-12 1995-08-29 Abbott Laboratories ((4-alkoxypyran-4-yl) substituted) ether, arylalkyl-, arylalkenyl-, and arylalkynyl)urea inhibitors of 5-lipoxygenase
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
JP2001506574A (ja) 1996-02-13 2001-05-22 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤およびロイコトリエンａ４ヒドロラーゼ阻害剤を含有する免疫抑制効果をもつ配合物
AU1850597A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
US6677364B2 (en) 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP1370140A1 (en) * 2000-10-03 2003-12-17 Syngenta Participations AG Phenylpropynyloxypyridine herbicides
GB2459809A (en) 2007-02-22 2009-11-11 Children S Hospital And Res Ct Fatty acid formulations and methods of use thereof
EP4276089A3 (en) 2016-03-03 2023-12-20 Universite De Moncton Modulators of lipoxygenase and cyclooxygenase enzyme activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743737A (en) * 1970-05-21 1973-07-03 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperindinylcarbinol compositions
CA960676A (en) * 1970-05-21 1975-01-07 Smith Kline And French Canada Ltd. 3-sulfonamido-4-hydroxyphenyl-2-piperidinylcarbinols
US3661917A (en) * 1970-05-21 1972-05-09 Smith Kline French Lab 3-sulfonamido-4-hydroxyphenyl-2-piperidylcarbinols
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
NZ213986A (en) * 1984-10-30 1989-07-27 Usv Pharma Corp Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such
US4625034A (en) * 1985-02-04 1986-11-25 Usv Pharmaceutical Corp. 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4876346A (en) * 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
US4920133A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
EP0349062A1 (en) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Quinoline ether alkanoic acid

Also Published As

Publication number Publication date
IE63211B1 (en) 1995-04-05
DE68913940T2 (de) 1994-07-14
GB8927287D0 (en) 1990-01-31
NZ231666A (en) 1992-01-29
FI896015A0 (fi) 1989-12-15
NO895087D0 (no) 1989-12-18
EP0375457B1 (en) 1994-03-16
CA2006095A1 (en) 1990-06-23
EP0375457A3 (en) 1991-01-09
US5098932A (en) 1992-03-24
AU622965B2 (en) 1992-04-30
JPH03135976A (ja) 1991-06-10
IE893881L (en) 1990-06-23
IL92580A (en) 1994-04-12
DK665089A (da) 1990-06-24
ES2063149T3 (es) 1995-01-01
AU4714789A (en) 1990-06-28
DK665089D0 (da) 1989-12-22
ZA899688B (en) 1990-08-29
HUT52494A (en) 1990-07-28
DE68913940D1 (de) 1994-04-21
IL92580A0 (en) 1990-08-31
EP0375457A2 (en) 1990-06-27
PT92701A (pt) 1990-06-29

Similar Documents

Publication Publication Date Title
NO895087D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive cykliske eter-derivater.
NO894630L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO871266D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO883974D0 (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO864126D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridon-derivater.
NO870526L (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO874032L (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO874153D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo-benzoksazinon-derivater.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO875488L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO893909D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
NO862372D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO891723D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO891114D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO864101D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO890607L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridin-derivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO874780D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolo-benzimidazol-derivater.
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO890724D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.